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ABSTRACT
Hot-melt extrusion is a viable technology in preparing the pharmaceutical delivery system
and has been considered as an attractive alternative to conventional processing methods. The
objective of this study was to utilize the advantage of continuous manufacturing in HME to design
and evaluate a formulation of topical semisolid ointment. Melt fusion ointments containing 5% of
acyclovir (ACV) in water-soluble base with PEG 400, PEG 1500, and PEG 3350 polymers at
various ratio were prepared. A design of experiment using I-optimal design was conducted. This
design was used to study the influence of polymer ratio on the physicochemical properties of the
formulations. The desired formulation was selected according to the critical quality attributes
(CQAs) including stiffness, adhesiveness, and pH. The selected formulation was then prepared
through HME with an 11 mm modified twin screw configuration and evaluated through texture
analysis, pH, drug content uniformity, differential scanning calorimetry (DSC), and in vitro drug
release. The result demonstrated that the selected formulation showed ideal properties required for
ointments. The pH is suitable for topical administration, DSC profile indicated the API was
completely dissolved in the base. In vitro drug release profile and drug content uniformity showed
no significant difference compared with the convention method under the same base ratio. Further,
ointment prepared by HME has a lower standard deviation in characterization data and has better
manufacturing efficiency compared with conventionally prepared ointment. In conclusion, hotmelt extrusion technology has been successfully applied to prepare water-soluble acyclovir
ointment and could be a promising and time-saving process used to develop semi-solid
formulations with better quality, consistency and manufacturing efficiency.
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LIST OF ABBREVIATIONS
ACV

Acyclovir

API

Active pharmaceutical ingredient

BHA

Butylated hydroxyanisole, 96%

BHT

Butylated hydroxytoluene

DoE

Design of Experiment

DSC

Differential Scanning Microscopy

HME

Hot-Melt Extrusion

HPLC

High-Performance Liquid Chromatography

IVRT

In vitro release testing

PB

Phosphate Buffer (pH 7.4, 0.1 M)

PEG

Polyethylene glycol

QbD

Quality by Design

QTTP

quality target product profile

RPM

Rate per minute

RSD

Relative standard deviation

SD

Standard deviation

TA

Texture analysis

UV-Vis

Ultraviolet-Visible Spectroscopy
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CHAPTER 1: DEVELOPMENT OF CONTINUOUS MANUFACTURING PROCESS OF
ACYCLOVIR OINTMENT USING HOT-MELT EXTRUSION
INTRODUCTION
Hot-melt extrusion (HME) is an established manufacturing process most widely used in
plastic and food industry. To date, this technology has been recognized by several research groups
as a viable method to prepare pharmaceutical drug delivery systems[1]. It is a process combining
mixing, melting raw materials with rotating screws under proper heat and pressure to create
homogenous mixtures of polymer and API[2]. Currently, HME has been utilized as a promising
alternative to traditional processing methods. It is an attractive technology and has various
advantages over other techniques. It is a green technology and does not cause any kind of pollution;
it is also a solvent-free process hence can be used with a variety of polymers and APIs. Furthermore,
HME is a continuous manufacturing process which makes it a far more sophisticated technique
than other pharmaceutical technologies since it is a unit operation and is very easy to scale up.
Therefore, it is one of the most economical pharmaceutical manufacturing technologies[3]. It can
be used to make several different formulations like immediate release, sustained release, controlled
release and targeted oral formulations[4]–[6]. Lately, it is also being used for topical and
transdermal drug deliveries[7]. It has also been used to produce films and is one of the best
technologies to be used alongside 3-dimensional printing[8].
Acyclovir (ACV) is a white, crystalline powder in nature with the molecular formula
C8H11N5O3 (Structure is shown in Figure 1) and a molecular weight of 225. The maximum
solubility in water at 37℃ is 2.5 mg/mL and has the pKa values of 2.27 and 9.25, indicates the
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presence of two different ionizable functional groups within its structure. ACV is presented in the
World Health Organization’s Model List of Essential Medicines as one of the most efficacious,
safe and cost-effective medicines in a basic health-care system.[9] It is a synthetic purine
nucleoside analogue and one of the most commonly used antiviral drugs for the treatment of herpes
simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV) infections. The
inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine
kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir
monophosphate, a nucleotide analogue, and is then further converted into diphosphate by cellular
guanylate kinase and into triphosphate by a number of cellular enzymes [10] Currently,
commercially marketed brand product is Zovirax 5% Ointment which contains 50 mg of ACV per
gram in polyethylene glycol(PEG) base. Acyclovir cream has been vigorously used for the
treatment of cold sores, and it is also used in capsule, tablet, topical and suspension formulations
for the treatment of various other viral infections with Acyclovir ointments being used as a primary
treatment for vaginal herpes. Melt fusion method is used for conventional preparation of ointment
Topical administration has the advantage of higher patient compliance over other routes of
administration but faces the manufacturing challenges of high time-consumption and inconsistent
mixing. The polyethylene glycol (PEG) is preferred as an ointment base comprising a mixture of
a low molecular weight PEG 400 and a higher molecular weight material such as PEG 3350. PEG
1500 was added to increase the hydrophilicity of the ointment base.
In the current study, the main objective was to utilize the advantage of the continuous
process of HME to formulate acyclovir 5% ointment as an achievable process for future industry.
Force stress degradation studies showed that ACV is stable in alkaline and remained stable under
the heating temperature of 70℃.[11] Its thermostability makes it a strong candidate for HME.
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Therefore, the significance of this work is to apply novel technology on preparing the semisolid
ointment as a potential replacement of the conventional method with potentially similar CQAs as
compared to the formulation prepared using traditional manufacturing methods.
Design of Experiment (DoE) is a structured, organized approach to find cause-and-effect
relationships between controlled input factors of the process and their responses.[12] It represents
the first choice for rational pharmaceutical development and has been intensively used for the
implementation of Quality by Design (QbD) in both research and industrial settings. The design
criteria for the formulation is described as Quality Target Product Profile (QTPP), which provide
the understanding of the quality, safety, and efficacy and form the basis of Critical Quality
Attributes (CQAs). There are various designs available today which can be used as a potential
element to estimate average prediction variance. The best options which could be considered
focusing on the optimality criteria are G-Optimal designs whose operations are based on
minimizing maximum prediction variance and I-Optimal designs whose operations are based on
minimizing average prediction variance. Borkowski and Rodriguez et al. [13]stated that while
using G-Optimal designs, it is occasionally expected to accept larger prediction variances to
minimize the maximum variance of prediction and therefore I-Optimal design was suggested over
G-Optimal design. In this study, mixture design was used to minimize the average prediction
variance. The mixture design had two different criterions which were under possible consideration,
D-Optimality criterion and I-optimality criterion. The selection of a better design to minimize the
average prediction variance was dependent on calculating the I efficiency of the designs. If P1 is
the average prediction variance of Design 1 and P2 is the average prediction variance of Design 2,
then the I efficiency of Design 1 would be P2/P1 and I effectiveness of Design 2 would be P1/P2.
It was found that the I effectiveness of I-Optimal design was larger than D-Optimal design. This
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is only possible if the average prediction variance of D-Optimal design is larger than that of IOptimal design. Because of this reason, Mixture I-Optimal design was used in this study to
minimize the average prediction variance of the model.[14]

Figure 1 Chemical Structure of Acyclovir
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MATERIALS AND METHODS
Chemicals
Acyclovir USP (>99%, Ria International, NJ); Polyethylene glycol 400 (PEG 400, Merck KGaA,
Germany); Polyethylene glycol 3350 (PEG 3350), Polyethylene glycol 1500 (PEG 1500),
Propylparaben (Lot No. 2CH0036), Methylparaben (Lot No. 2BK0012) were all purchased from
Spectrum Chemicals, Gardena, CA; Butylated hydroxytoluene (BHT, Lot No. Q1443, MP
Biomedicals, LCC, Solon, OH); Sodium phosphate dibasic heptahydrate (MW: 268 g/mol),
Sodium phosphate monobasic monohydrate (MW: 138 g/mol), Sodium hydroxide pellets (pure,
Lot: A0340458), Butylated hydroxyanisole (BHA, 96%, Lot: A0336138) were all purchased from
ACROS Organics; Hydrochloric acid (Certified ACS Plus, Fisher Chemical, Canada).

DoE
The experimental design was proposed using I-optimal mixture design. This experiment was
selected based on the minimum average prediction variance. The formulations were differentiated
by various specified ratios of PEG 400 with PEG 1500 and PEG 3350(1:1). The software used for
the application of DoE was Design Expert 11. The target profile of the optimized formulation is
shown in Table 1
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Table 1 Formulation compositions screening of acyclovir ointments
Formulation No.

PEG 400

PEG 1500 : PEG 3350 (1:1)

F1

70

30

F2

65

35

F3

60

40

F4

55

45

F5

50

50

F6

75

25

F7

80

20

*all formulations contain 5% of Acyclovir Ointment, 0.2% of Methylparaben, 0.02% of
Propylparaben, 0.01% of BHA, 0.02% of BHT
Table 2 Target profile of Acyclovir Ointment
Elements
Dosage Form
Route of
Administration
Dosage strength

Target
Ointment

Dosage design

Water-soluble ointment

Assay

90.0 -110.0 %

Appearance

White, smooth

Content
Uniformity
pH

CQA

Topical
5.00%

USP Chapter <3>
5.5-7.0

Yes

Adhesiveness

Consistent

Yes

Stiffness

Consistent

Yes

In vitro release
testing

Rate of release of the drug
concerning the square root of
time, R²>0.90

Yes
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Preparation of Conventional Ointment
Water-miscible ointment base composed of PEGs were prepared by the conventional method of
fusion. A predetermined amount of PEG 400, PEG 3350, and PEG 1500 and other excipients were
weighed. PEG 400 was mixed with API first in a mortar while PEG 3350 and PEG 1500 were
warmed first to around 65  5℃ on a hot plate. Combined the two mixtures on the hot plate and
wait for a minute to uniform the temperature. Stirring the mixture under 65  5℃ until
homogenized and removed from the hot plate, transferred to a mortar and stirred until congealed.
Preparation of Hot-Melt Extruded Ointment
In this study, 11 mm co-rotating twin-screw extruder (Process 11 twin screw extruder, Thermo
Fisher Scientific) was used.[15] The schematic representation and assembly of the extruder are
shown in Figure 2 and Figure 3, respectively. Before the manufacturing process, the calibrations
of the volumetric feeder, portal of the solid phase, and the peristaltic pump, injection of the liquid
phase are necessary, in order to make sure the solid phase and liquid phase are mixed at an accurate
ratio. A calibration curve was prepared with the correlation of weight dispensed per minute
(mg/min) vs. feeder’s set point and weight dispensed per minute vs. RPM (Pump). 5% of ACV
was mixed with PEG 3350 and PEG 1500 to obtain the physical mixtures (PMs). The PMs were
added through a volumetric feeder at zone 1, and PEG 400 was introduced in the extruder barrel
in zone 3, using a peristaltic pump and an injection port after 2 minutes. Extrusion condition was
under the temperature of 65 ℃ from zone 1 to 5 and 40 ℃ for the rest of the zones. The screw
configuration was designed with three mixing zone including a mixing zone for PMs, a terminal
mixing zone to prevent phase separation, and an extended mixing zone at zone 3 where PEG 400
was injected in to the extruder. The liquid extrudates were collected in one white plastic sealed
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container and cooled at ambient temperature. The container was stored in dry, dark conditions for
further characterizations.

Table 3 Finalized formulation
Feeding Phase

Ingredients

%wt

Solid

PEG 3350
PEG 1500
ACV
BHT
BHA
Propyl Paraben
Methyl Paraben
PEG 400

11.84
11.84
5
0.02
0.01
0.02
0.2
71.06

Liquid

Table 4 Parameters maintained for HME process
Parameters

Description

Equipment

11 mm co-rotating twin screw extruder

Screw Design

Modified screw

Barrel Temperature

Zone 1-5 (65℃)
Zone 6-8, Exit (40℃)

Pump Feeding Rate

2 RPM

Torque

0-2%

Screw Speed

60 RPM

8

Figure 2 Schematic representation of the preparation of ointment by HME

Figure 3 Screw design used for the preparation of ointments
Differential Scanning Calorimetry (DSC)
DSC studies were performed to determine the drug-excipient compatibility, melting point, and
polymorphism or degradation. In this study, pure API, pure base of PEG 3350 and PEG 1500, and
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drug load ointments formulations by conventional and HME method were physically characterized
using DSC 25 (TA instruments) along with a Trois software for analyzing the data. DSC
Approximately 2-5 mg of each sample was weighed and sealed in an aluminum hermetic pan to
prevent evaporation. The temperature range of the sample was from 25 to 275 ℃ at a heating rate
of 10 ℃/min under inert nitrogen atmosphere maintaining a flow rate of 50 mL/min

pH measurement
pH was considered to be a critical quality attribute; therefore, the desired pH of the formulation
should within the range of 5.5 - 7.0 according to pH of normal human skin. Metteler Toledo InLab
®Micro pH probe (electrolyte 3 mol/L KCl) was used in this test. Predetermined amount of
formulation was dissolved in water and pH was measured with the two different concentrations of
5 % w/v,10% w/v. [15]

Texture Analysis
Texture Analysis was used to determine the texture properties, stiffness and Adhesiveness to be
specific in this study. The experiment was conducted on the texture analyzer TA.XT2i (Texture
Technologies Corp., Scarsdale, NY, USA) with software Texture Exponent 32 (Stable Micro
Systems) along with a 1-inch diameter probe (TA-3, acrylic cylindrical), and a soft matter kit (TA275). The experimental protocol for texture analysis is listed in Table 5
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Table 5 TA Experimental Protocol
Settings

Parameters

Unit

Sequence Title

3 HOLD UNTIL TIME

Test Mode

Compression

Pre-Test Speed

0.5

mm/sec

Test Speed

0.5

mm/sec

Post-test Speed

5

mm/sec

Target Mode

Distance

Force

100

g

Distance

2

mm

Strain

10

%

The ointments were applied onto the soft matter and positioned below the texture analyzer’s probe.
Once the test started, the problem was moving toward the product at pre-text speed till it touched
the surface of the ointment. The probe produced a deformation of 2 mm of the sample at the test
speed after reaching the surface and establishing the trigger force. Then, the probe was detached
from the sample at post-text speed. Before each test, the base of the probe and the surface of the
soft matter was properly cleaned. Each of the formulations was run in triplicated[16].

Method of analysis
ACV content was determined using UV-Visible Spectrometer (Thermo Scientific, Genesys 180)
equipped with 1 cm matched quartz cuvette under the maximum absorbance wavelength of 254
nm. Weighted amount of ACV powder equivalent to 100 mg was dissolved 100 mL of 0.1 N
NaOH. A series of standard solutions containing 1.0-50 µg/mL of ACV were prepared and
measured under the wavelength against reagent blank.
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Uniformity of Drug Content
ACV content in both Conventional method and HME method were estimated by this method.
Carefully weighted 0.2 g of formulation equivalent to 10 mg off API were taken from different
regions of the container and mixed with 2 mL Acetonitrile, vortex for 20 seconds and centrifuge
for 10 minutes with 13,000 rpm at room temperature until the PEG base was completed dissolved.
Remove the supernatant and add 2mL 0.1 N NaOH as extortion medium to dissolve the drug at a
concentration of 5 mg/mL. After achieving the complete solubility of the drugs, a 100 µL of
solution was transferred into 20 mL scintillation vials with 0.1 N NaOH to obtain the concentration
of 25 µg/mL. The samples were then analyzed by UV-Vis method at maximum wavelength of 254
nm to determine the drug amount of ACV using the calibration curve above[17], [18].

In Vitro Release Testing (IVRT)
The in vitro release testing (IVRT) of conventional and HME ointment equivalent to 50mg of ACV
was confirmed using modified dissolution apparatus II (immersion cells) and 150 mL capacity
flask containing freshly prepared Phosphate Buffer (PB, 0.1 N, pH 7.4). SR8-plus dissolution tester
(Hanson, Chatsworth, US) was maintained at 32 ± 0.5°C and the paddle speed was set at 50 rpm.
The membrane was selected to be a hydrophobic Tuffryn membrane (0.45 um, 25mm, 1.77
cm2)[19] and assembled as is shown in the guide[20]. Before starting the dissolution, the
membrane was pre-wet in the dissolution media for 30 minutes. Ointments were applied onto the
membrane and sealed inside the cell. The infinite dose of the ointment formulation was applied to
the membrane. The active diffusion area of the membrane was 1.77 cm2. During the study, 1 mL
of sample was collected from the flask at time points of 0.5, 1, 2, 3, 4, and 5 hours, respectively.
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Then, an equal amount of fresh buffer was injected as subsequent. The collected samples were
suitably diluted and analyzed using UV-Vis system at the wavelength of 254 nm.

Figure 4 a) Assembly diagram, b) immersion cell components, c) SR8-Plus Configuration[20]
©2012 Hanson Research Corp.
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RESULTS AND DISCUSSION
Formulation Screening
Screening of the formulations was performed based on CQAs with three essential parameters:
stiffness, adhesiveness, and pH. Texture parameters such as firmness and adhesiveness of semisolids are essential for product performance as well as for patient’s compliance. Stiffness relates
to the viscosity of the product and is denoted by the maximum value of force in the plot of force
versus time. The adhesiveness relates to spreadability, and it is the area under the negative area
under the curve. Suitable formulations were selected based on the CQAs.
Table 6 Screening of the formulations
Formulation No.

Stiffness (g)

Adhesiveness (g.sec)

pH

F1

974.348

397.723

5.63

F2

1255.828

585.299

5.47

F3

2046.877

532.354

5.69

F4

3221.873

331.856

5.82

F5

3843.933

412.128

6.62

F6

683.094

367.808

5.58

F7

437.318

259.561

5.36

All the formulations had a different ratio of PEG base and significance has been found only in
stiffness between each ratio, which means there is no significant effect of and pH on the
formulations. It can be further demonstrated by p-value greater than 0.05.
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Adhesiveness
Table 7 ANOVA of the tested formulation for adhesiveness
Source

Sum of
Squares

df

Mean Square

Fvalue

p-value

Model

0.0002

2

0.0001

2.83

0.1509

⁽¹⁾Linear
Mixture
AB
Residual

0

1

0

0.8712

0.3935

0.0001
0.0002

1
5

0.0001
0

4.78

0.0804

Lack of Fit

0.0002

4

0

25.91

0.1462

Pure Error
Cor Total

1.46E-06
0.0003

1
7

1.46E-06

not
significant

not
significant

The Model F-value of 2.83 implies the model is not significant relative to the noise. There is a
15.09% chance that an F-value this large could occur due to noise. P-values less than 0.0500
indicate model terms are significant. In this case A, B are significant model terms. Values higher
than 0.1000 indicate the model terms are not significant. If there are many insignificant model
terms (not counting those required to support hierarchy), model reduction may improve your
model. The Lack of Fit F-value of 25.91 implies the Lack of Fit is not significant relative to the
pure error. There is a 14.62% chance that a "Lack of Fit F-value" this large could occur due to
noise. Non-significant lack of fit is good -- we want the model to fit.
Table 8 Fit statistics for the design
Std. Dev.
Mean
C.V. %

0.0055
0.0512
10.8

R²
Adjusted R²
Predicted R²
Adeq Precision

0.5307
0.343
-0.6914
4.3218

A negative Predicted R² implies that the overall mean may be a better predictor of your response
than the current model. In some cases, a higher order model may also predict better. Adeq Precision
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measures the signal to noise ratio. A ratio greater than 4 is desirable. The ratio of 4.322 indicates
an adequate signal. This model can be used to navigate the design space.
Table 9 Coefficients in terms of coded factors
Component
A-PEG 400
B-PEG 3350: PEG
1500
AB

Coefficient
Estimate
0.0608

1

Standard
Error
0.0048

95% CI
Low
0.0484

95% CI
High
0.0732

1.94

0.0553

1

0.0045

0.0437

0.0669

2.14

-0.0475

1

0.0217

-0.1033

0.0083

3.38

df

VIF

The coefficient estimate represents the expected change in response per unit change in factor value
when all remaining factors are held constant. The intercept in an orthogonal design is the overall
average response of all the runs. The coefficients are adjustments around that average based on the
factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1 indicate multicolinearity, the higher the VIF the more severe the correlation of factors. As a rough rule, VIFs
less than 10 are tolerable.

Figure 5 Two Component mix plots with varying ratios of PEG base in the formulations
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Figure 6 Predicted versus actual values of adhesiveness for the formulations
Stiffness
Table 10 ANOVA of the tested formulations for Force
Source

Sum of Squares

df

Model
⁽¹⁾Linear
Mixture
AB
AB(A-B)
AB(A-B)²
Residual
Lack of Fit
Pure Error
Cor Total

0.0009

4

Mean
Square
0.0002

0.0009

1

0
2.71E-07
4.72E-06
7.91E-07
7.74E-07
1.69E-08
0.0009

1
1
1
3
2
1
7

F-value

p-value

858.22

< 0.0001

0.0009

3323.64

< 0.0001

0
2.71E-07
4.72E-06
2.64E-07
3.87E-07
1.69E-08

70.56
1.03
17.91

0.0035
0.3854
0.0241

22.92

0.1461

significant

not significant

The Model F-value of 858.22 implies the model is significant. There is only a 0.01% chance
that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model
terms are significant. In this case, A, B, AB, AB(A-B)² are significant model terms. Values higher
than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 22.92 implies

17

the Lack of Fit is not significant relative to the pure error. There is a 14.61% chance that a "Lack
of Fit F-value" this large could occur due to noise. Non-significant lack of fit is good -- we want
the model to fit.
Table 11 Fit statistics for the design
Std. Dev.
Mean
C.V. %

0.0005
0.0274
1.87

R²
0.9991
0.998
Adjusted R²
0.9782
Predicted R²
78.2092
Adeq Precision
The Predicted R² of 0.9782 is in reasonable agreement with the Adjusted R² of 0.9980; i.e. the
difference is less than 0.2. Adeq Precision measures the signal to noise ratio. A ratio greater than
4 is desirable. The ratio of 78.209 indicates an adequate signal. This model can be used to
navigate the design space.
Table 12 Coefficients in terms of coded factors
Component
A-PEG 400
B-PEG 3350: PEG 1500
AB
AB(A-B)
AB(A-B)²

Coefficient Estimate
0.0479
0.0161
-0.0174
-0.0036
-0.03

df Standard Error 95% CI Low 95% CI High
1
0.0005
0.0463
0.0495
1
0.0005
0.0145
0.0178
1
0.0021
-0.0239
-0.0108
1
0.0036
-0.0151
0.0078
1
0.0071
-0.0525
-0.0074

VIF
2.52
3.18
3.55
1.79
2.41

The coefficient estimate represents the expected change in response per unit change in factor value
when all remaining factors are held constant. The intercept in an orthogonal design is the overall
average response of all the runs. The coefficients are adjustments around that average based on the
factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1 indicate multicolinearity, the higher the VIF the more severe the correlation of factors. As a rough rule, VIFs
less than 10 are tolerable.
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Figure 7 Two component mix plots with varying ratios of PEG base in the formulations

Figure 8 Predicted versus actual plot for the values of Force for different formulations
Figure 8 shows that stiffness of the formulation decreases with an increase in the PEG 400
concentration. The ratio between low molecular weight and high molecular weight of PEG
significantly affects the stiffness of the ointment formulation. Hence, the desired stiffness can be
predicted using this parameter in the software.

PH
The pH of F2 (5.47) and F7 (5.36) are out of the selected range (5.5-7.0) of design space. The pH
of all other formulations fall in the range, therefore it can be assumed that it has no significant
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correlation with different formulation ratio, hence would no longer be considered as a parameter
for formulation screening.

Optimization and Manufacturing process
After the ratio screening of conventionally prepared formulations, F6 (75:25) with desirable
properties was selected to be formulated using both conventional method and HME. They were
then characterized for pH, texture, drug content uniformity, differential scanning calorimetry
(DSC), and in vitro drug release.

DSC analysis
DSC is used as thermal analysis to ensure the API dissolved adequately in the formulations. The
thermogram shows that API was characterized by two endothermic peaks, indicating its melting
point at 257 ℃ (Figure 9) and its polymorph anhydrous form V at about 150 ℃ [21]. PEG 3350
and PEG 1500 are semi-crystalline polymers and were found to melt in the range of 60-70℃ and
40-50 ℃, respectively. After extrusion, the endotherm peaks of API were not preserved since the
drug has completely dissolved. There is partial crystallization seen in the formulations which can
be attributed to PEG since the characteristic peak of PEG has subsided and has shifted to a slightly
lower temperature.
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Figure 9 DSC thermogram of Acyclovir, excipients and different ointment formulations

Uniformity of Drug Content
Uniform mixing of the API with ointment base is one of the challenging tasks in manufacturing of
topical semi-solids. Uniformity of drug content indicates the efficiency of the mixing process. In
this study, we found that the drug content in the hot-melt extruded ointment was 94.27 % ± 0.64%,
and in the conventional ointment was 97.84% ± 0.98%. Both of the formulations are within the
targeted range between 90 – 110 %, indicated the suitability for ointment base.[22] It is evident
from the result that modified screw configuration used in the study was effective resulting in a
product with uniform drug content.
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Table 13 Formulation properties
Formulation
HME
Conventional

Drug Content
94.27 % ±0.64%
97.84% ± 0.98%

Adhesiveness
358.930 ± 5.434
361.526 ± 19.629

Stiffness
684.840 ± 5.375
669.328 ± 14.277

pH
5.67 ± 0.07
5.63 ± 0.14

In vitro Release testing (IVRT)
The immersion cells apparatus was used to assess the release of acyclovir from both of the
formulations using Tuffryn membrane in phosphate buffer (0.1N, pH 7.4). The immersion cell
method is a modified USP Apparatus II, which is the most readily available apparatus used by
most researchers worldwide. It has been reported the advantage of better consistency compared
with diffusion cells in earlier research[23], [24]. Besides, the membrane selection is essential in
IVRT because different physicochemical properties of the commercially available synthetic
membranes may have different influence on release rate. Tuffryn membrane was selected because
the lower protein binding property is more preferable for acyclovir as a relatively polar drug[25].
The in vitro drug release studies were carried out for 5 hours. Data were linearized using the square
root of time transformation and linear plots were obtained by plotting the cumulative amounts
released per square root of time. The coefficient of determination was R2 > 0.95 (P=0.68, P>0.05),
indicated no significant difference observed between conventionally prepared formulation and
HME formulation.
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Figure 10 In vitro drug release profile of conventional and HME formulation
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CONCLUSION
In this study, topical ointments of 5% acyclovir were prepared by the HME technology as well as
the conventional technique and characteristic properties were compared between the formulations.
It can be confirmed from the DSC profile that model API has completely dissolved in the excipient.
No degradation was observed in the formulation profile. The CQAs, including texture and in-vitro
release testing from HME showed similar results with conventional formulations. It was observed
that on increasing the concentration of solid phase (PEG 3350 and PEG 1500) the stiffness
increased to a certain point and then the stiffness started decreasing. pH and adhesiveness were
barely influenced by the composition ratio. Therefore, according to the design, it can be observed
that stiffness is significantly influenced by the composition of different formulations. Further, it
was noticeable that formulations prepared by HME have a lower standard deviation in the
characterization results, indicating the advantage of consistent and reproducible results of HME.
In conclusion, the HME technology has been successfully applied to prepare semisolid dosage
form and could be a promising and time-saving process used to develop semi-solid formulations
with better quality, consistency and manufacturing efficiency.

24

LIST OF REFERENCES

25

[1] M. M. Crowley et al., “Pharmaceutical Applications of Hot-Melt Extrusion: Part I,” Drug
Dev. Ind. Pharm., vol. 33, no. 9, pp. 909–926, Jan. 2007.
[2] M. Maniruzzaman, J. S. Boateng, M. J. Snowden, and D. Douroumis, “A Review of HotMelt Extrusion: Process Technology to Pharmaceutical Products,” ISRN Pharm., vol. 2012,
Dec. 2012.
[3] M. A. Repka et al., “Pharmaceutical Applications of Hot-Melt Extrusion: Part II,” Drug Dev.
Ind. Pharm., vol. 33, no. 10, pp. 1043–1057, Jan. 2007.
[4] W. De Jaeghere, T. De Beer, J. Van Bocxlaer, J. P. Remon, and C. Vervaet, “Hot-melt
extrusion of polyvinyl alcohol for oral immediate release applications,” Int. J. Pharm., vol.
492, no. 1–2, pp. 1–9, 2015.
[5] M. Fukuda, N. A. Peppas, and J. W. McGinity, “Floating hot-melt extruded tablets for
gastroretentive controlled drug release system,” J. Controlled Release, vol. 115, no. 2, pp.
121–129, Oct. 2006.
[6] “Ethylene vinyl acetate as matrix for oral sustained release dosage forms produced via hotmelt extrusion - ScienceDirect.” [Online]. Available:
https://www.sciencedirect.com/science/article/abs/pii/S093964111000322X. [Accessed: 21Apr-2019].
[7] M. A. Repka, S. Majumdar, S. Kumar Battu, R. Srirangam, and S. B. Upadhye,
“Applications of hot-melt extrusion for drug delivery,” Expert Opin. Drug Deliv., vol. 5,
no. 12, pp. 1357–1376, 2008.

26

[8] J. Zhang, X. Feng, H. Patil, R. V. Tiwari, and M. A. Repka, “Coupling 3D printing with hotmelt extrusion to produce controlled-release tablets,” Int. J. Pharm., vol. 519, no. 1, pp.
186–197, Mar. 2017.
[9] M. M. Al-Subaie, K. M. Hosny, K. M. El-Say, T. A. Ahmed, and B. M. Aljaeid, “Utilization
of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of
herpes simplex viral infections,” International Journal of Nanomedicine, 15-Jun-2015.
[Online]. Available: https://www.dovepress.com/utilization-of-nanotechnology-to-enhancepercutaneous-absorption-of-ac-peer-reviewed-article-IJN. [Accessed: 15-Apr-2019].
[10] G. B. Elion, “Mechanism of action and selectivity of acyclovir,” Am. J. Med., vol. 73, no.
1A, pp. 7–13, Jul. 1982.
[11] V. R. Sinha, Monika, A. Trehan, M. Kumar, S. Singh, and J. R. Bhinge, “Stress Studies on
Acyclovir,” J. Chromatogr. Sci., vol. 45, no. 6, pp. 319–324, Jul. 2007.
[12] S. N. Politis, P. Colombo, G. Colombo, and D. M. Rekkas, “Design of experiments (DoE)
in pharmaceutical development,” Drug Dev. Ind. Pharm., vol. 43, no. 6, pp. 889–901, Jun.
2017.
[13] M. Rodríguez, B. Jones, C. M. Borror, and D. C. Montgomery, “Generating and Assessing
Exact G-Optimal Designs,” J. Qual. Technol., vol. 42, no. 1, pp. 3–20, Jan. 2010.
[14] P. Goos, B. Jones, and U. Syafitri, “I-Optimal Design of Mixture Experiments,” J. Am. Stat.
Assoc., vol. 111, no. 514, pp. 899–911, Apr. 2016.
[15] A. M. Bhagurkar et al., “Development of an Ointment Formulation Using Hot-Melt
Extrusion Technology,” AAPS PharmSciTech, vol. 17, no. 1, pp. 158–166, Dec. 2015.

27

[16] A. Tai, R. Bianchini, and J. Jachowicz, “Texture analysis of cosmetic/pharmaceutical raw
materials and formulations,” Int. J. Cosmet. Sci., vol. 36, no. 4, pp. 291–304, Aug. 2014.
[17] “Acyclovir Ointment USP, 5%.,” p. 4.
[18] N. R. Padala, D. Baishakhi, F. H. Assaleh, P. Katakam, and B. R. Chandu, “UVSPECTROPHOTOMETRIC ESTIMATION OF ACYCLOVIR IN BULK AND
PHARMACEUTICAL DOSAGE FORMS,” J. Pharm. Sci. Innov., vol. 2, no. 4, pp. 40–43,
Jul. 2013.
[19] S. Nallagundla, S. Patnala, and I. Kanfer, “Comparison of In Vitro Release Rates of
Acyclovir from Cream Formulations Using Vertical Diffusion Cells,” AAPS PharmSciTech,
vol. 15, no. 4, pp. 994–999, Aug. 2014.
[20] https://files.hansonresearch.com/wp-content/uploads/2015/03/Dissolution-Immersion-CellUser-Guide.pdf
[21] K. M. Lutker, R. Quiñones, J. Xu, A. Ramamoorthy, and A. J. Matzger, “Polymorphs and
Hydrates of Acyclovir,” J. Pharm. Sci., vol. 100, no. 3, pp. 949–963, Mar. 2011.
[22] “United States Pharmacopeia and National Formulary (USP 41-NF 36).” .
[23] P. Kumar, P. Sanghvi, and C. C. Collins, “Comparison of Diffusion Studies of
Hydrocortisone Between the Franz Cell and the Enhancer Cell,” Drug Dev. Ind. Pharm.,
vol. 19, no. 13, pp. 1573–1585, Jan. 1993.
[24] N. Kobayashi and I. Saitoh, “Development of a Test Method for in Vitro Drug Release
from Soluble and Crystal Dispersion Type Ointments,” 1999.

28

[25] S. Nallagundla, S. Patnala, and I. Kanfer, “Comparison of In Vitro Release Rates of
Acyclovir from Cream Formulations Using Vertical Diffusion Cells,” AAPS PharmSciTech,
vol. 15, no. 4, pp. 994–999, May 2014.

29

VITA
Rui Wang was born and raised in Beijing, China, in 1994. She received her diploma in
bachelors of engineering in Pharmaceutics in 2017 from Shenyang Pharmaceutical University. She
published a research article in the International Journal of Pharmaceutic in 2017, a mini-review
article in AAPS PharmSciTech in 2018, and has contributed to a book chapter on Brain-Targeted
Drug Delivery in press. She was inducted into Phi Kappa Phi, the nation’s oldest and most selective
all-discipline honor society on April 10, 2019. Upon graduation, she is going to continue her
endeavors in the Department of Pharmaceutical Sciences as a Ph.D. student at the University of
Tennessee Health Science Center in Fall 2019 under Dr.Wei Li’s supervision.

30

